Inventor · disambiguated record
Huamao Wang
Also filed as: WANG HUAMAO
19 granted patents·19 pending applications·55 citations·filing 2009–2024
92Inventor score
Files withCRAGE MEDICAL CO LTD14CAFA THERAPEUTICS LTD8CARSGEN THERAPEUTICS CO LTD7SHANGHAI YILE BIOTECHNOLOGY CO LTD4CARSGEN THERAPEUTICS LTD3
Top patents by PatentIndex Score
38 records- 0193US11525006B2BCMA-targeting antibody and use thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Dec 13, 2022·6 cites·24 claims
- 0292US11111295B2Antibody for anti-claudin 18A2 and use thereofCAFA THERAPEUTICS LTD·Filed 2017·Granted Sep 7, 2021·7 cites·29 claims
- 0389US8506963B2Anti-EFGRv3 monoclonal antibodyLI ZONGHAI·Filed 2009·Granted Aug 13, 2013·16 cites·9 claims
- 0487US10377822B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCARSGEN THERAPEUTICS LTD·Filed 2015·Granted Aug 13, 2019·5 cites·13 claims
- 0586US10793641B2Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelinCARSGEN THERAPEUTICS CO LTD·Filed 2016·Granted Oct 6, 2020·5 cites·30 claims
- 0685US11198729B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Granted Dec 14, 2021·3 cites·11 claims
- 0783US2025230232A1Immunologic effector cell of targeted cld18a2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 0882US10023639B2Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigenCARSGEN THERAPEUTICS CO LTD·Filed 2013·Granted Jul 17, 2018·6 cites·8 claims
- 0979US10731127B2Chimeric antigen receptors targeting GPC3 and uses thereofCARSGEN THERAPEUTICS LTD·Filed 2014·Granted Aug 4, 2020·3 cites·19 claims
- 1079US2024342305A1Antibody against glypican-3 and application thereofCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 1178US9969799B2Anti-human proBDNF monoclonal antibody, and uses thereof in painsSHANGHAI YILE BIOTECHNOLOGY LTD·Filed 2015·Granted May 15, 2018·4 cites·16 claims
- 1276US2025177544A1Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 1375US12098199B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Granted Sep 24, 2024·0 cites·10 claims
- 1470US2024269175A1Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2023·Application pending·0 cites
- 1567US12186343B2Method and composition for treating tumorsCRAGE MEDICAL CO LTD·Filed 2019·Granted Jan 7, 2025·0 cites·20 claims
- 1667US11596653B2Compositions and methods of cellular immunotherapyCRAGE MEDICAL CO LTD·Filed 2018·Granted Mar 7, 2023·0 cites·29 claims
- 1767US2022185880A1Antibody for anti-claudin 18a2 and use thereofCAFA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1866US2025114438A1Method for treating tumor using immune cellCARSGEN THERAPEUTICS CO LTD·Filed 2024·Application pending·0 cites
- 1964US12435119B2Genetically engineered cell and application thereofCRAGE MEDICAL CO LTD·Filed 2019·Granted Oct 7, 2025·0 cites·38 claims
- 2064US2022017625A1Tumor-specific anti-egfr antibody and application thereofCAFA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2160US12168061B2Antibody against glypican-3 and application thereofCRAGE MEDICAL CO LTD·Filed 2016·Granted Dec 17, 2024·0 cites·26 claims
- 2254US10927176B2Tumor-specific anti-EGFR antibody and application thereofCARSGEN THERAPEUTICS CO LTD·Filed 2016·Granted Feb 23, 2021·0 cites·5 claims
- 2353US2023148586A1Low-temperature storage of biological samplesCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 2453US2023061005A1Anti-claudin 18.2 antibody and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Application pending·0 cites
- 2551US2022033491A1Combination therapy of cldn18 antibody and chemotherapy drugsCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2651US2022096544A1Chemokine expressing cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2750US2022127570A1Immune effector cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2850US2021292427A1Method for treating tumor using immune effector cellCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2950US2021017264A1Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factorSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
- 3048US10556947B2Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factorSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2017·Granted Feb 11, 2020·0 cites·17 claims
- 3148US2020347410A1Synnotch receptor-regulated expression of il12CARSGEN THERAPEUTICS CO LTD·Filed 2019·Application pending·0 cites
- 3245US2024182920A1Method for transducing cells with viral vectorCARSGEN THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 3343US11530270B2Antibody targeting IL-13RA2 and use thereofCRAGE MEDICAL CO LTD·Filed 2018·Granted Dec 20, 2022·0 cites·13 claims
- 3442US2022064274A1Use of probdnf regulator in b cell-related diseasesSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
- 3538US11479603B2Polypeptide and antibody bound to polypeptideSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2018·Granted Oct 25, 2022·0 cites·5 claims
- 3638US2019359989A1Fusion protein and applications thereofCARSGEN THERAPEUTICS CO LTD·Filed 2017·Application pending·0 cites
- 3736US2018105595A1Time and space adjustable system for inhibiting pathological target cellsCARSGEN THERAPEUTICS LTD·Filed 2015·Application pending·0 cites
- 3835US11453860B2GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereofCRAGE MEDICAL CO LTD·Filed 2015·Granted Sep 27, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Huamao Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →